US Stock MarketDetailed Quotes
CMMB Chemomab Therapeutics
- 1.820
- +0.040+2.25%
Close Nov 29 13:00 ET
- 1.820
- 0.0000.00%
Post 16:10 ET
34.32MMarket Cap-1936P/E (TTM)
1.860High1.750Low37.41KVolume1.790Open1.780Pre Close67.63KTurnover0.32%Turnover RatioLossP/E (Static)18.86MShares2.55052wk High2.10P/B21.51MFloat Cap0.42052wk Low--Dividend TTM11.82MShs Float184.000Historical High--Div YieldTTM6.18%Amplitude0.420Historical Low1.807Avg Price1Lot Size
Chemomab Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | (FY)Dec 31, 2021 | (Q4)Dec 31, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -15.91%-23.61M | -31.31%-7.49M | -93.64%-7.19M | -64.62%-20.37M | -97.06%-5.7M | -103.68%-5.26M | -1.68%-5.7M | -187.01%-3.71M | -136.05%-12.37M | -86.11%-2.89M |
| Net income from continuing operations | 12.39%-24.22M | -28.76%-7.97M | -71.49%-8.75M | -121.56%-27.65M | -64.26%-8.27M | -172.24%-8.08M | -123.47%-6.19M | -199.53%-5.1M | -109.68%-12.48M | -158.12%-5.04M |
| Depreciation and amortization | 15.52%67K | 14.29%16K | 23.08%16K | 70.59%58K | 27.27%14K | 88.89%17K | 100.00%14K | 85.71%13K | 41.67%34K | 83.33%11K |
| Change In working capital | -123.66%-948K | 40.21%-171K | 110.87%1.07M | 305.59%4.01M | 61.62%1.82M | 3,280.65%1.97M | 91.52%-286K | 40.17%506K | -451.17%-1.95M | 214.57%1.12M |
| -Change in receivables | 1,510.94%903K | 99.73%-3K | 324.24%814K | 96.89%-64K | 516.09%536K | 129.95%883K | 56.69%-1.12M | -736.84%-363K | -1,978.79%-2.06M | 229.85%87K |
| -Change in payables and accrued expense | -135.50%-1.13M | -229.51%-531K | -62.68%315K | 3,152.88%3.18M | 48.56%1.24M | 362.16%679K | 145.56%410K | 285.39%844K | -122.61%-104K | 155.66%836K |
| -Change in other current liabilities | ---- | ---- | -125.00%-3K | ---- | ---- | --0 | ---27K | --12K | ---- | ---- |
| -Change in other working capital | -180.80%-724K | -20.18%360K | -553.85%-59K | 320.66%896K | -89.00%22K | 319.25%410K | 292.17%451K | -84.71%13K | 9.79%213K | 106.19%200K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -15.91%-23.61M | -31.31%-7.49M | -93.64%-7.19M | -64.62%-20.37M | -97.06%-5.7M | -103.68%-5.26M | -1.68%-5.7M | -187.01%-3.71M | -136.05%-12.37M | -86.11%-2.89M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -18.71%15.88M | -347.13%-4.27M | 505.88%14.43M | 143.23%19.53M | 147.75%9.35M | 221.48%6.07M | 108.38%1.73M | 119,200.00%2.38M | -72,780.65%-45.19M | -652,600.00%-19.58M |
| Net PPE purchase and sale | 95.59%-3K | 81.82%-2K | 92.86%-1K | 71.06%-68K | 99.23%-1K | ---42K | 89.22%-11K | -366.67%-14K | -518.42%-235K | -12,900.00%-130K |
| Net investment purchase and sale | ---- | -345.45%-4.27M | 502.38%14.43M | ---- | ---- | ---- | --1.74M | --2.4M | ---- | ---- |
| Net other investing changes | -18.97%15.88M | ---- | ---- | 143.61%19.6M | 148.07%9.35M | ---- | ---- | ---- | ---44.95M | ---19.45M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -18.71%15.88M | -347.13%-4.27M | 505.88%14.43M | 143.23%19.53M | 147.75%9.35M | 221.48%6.07M | 108.38%1.73M | 119,200.00%2.38M | -72,780.65%-45.19M | -652,600.00%-19.58M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 533.66%3.5M | -101.32%-808K | -972.84%-869K | 154.17%39K | 1,185.77%61.07M | -114.39%-81K | ||||
| Net common stock issuance | 468.45%3.5M | ---- | ---- | -101.62%-951K | -945.05%-951K | --0 | ---- | ---- | 1,575.34%58.64M | -118.20%-91K |
| Proceeds from stock option exercised by employees | --0 | ---- | ---- | 1,330.00%143K | 720.00%82K | --39K | ---- | ---- | -99.20%10K | -98.22%10K |
| Net other financing activities | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --2.43M | --0 |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 533.66%3.5M | 6,118.18%1.37M | --0 | -101.32%-808K | -972.84%-869K | 154.17%39K | -99.84%22K | --0 | 1,185.77%61.07M | -114.39%-81K |
| Net cash flow | ||||||||||
| Beginning cash position | -10.79%13.6M | 49.81%20.84M | -10.79%13.6M | 29.97%15.24M | -71.38%10.82M | -78.09%9.96M | -76.11%13.91M | 29.97%15.24M | -4.51%11.73M | 197.01%37.8M |
| Current changes in cash | -157.02%-4.23M | -162.80%-10.39M | 645.22%7.25M | -146.81%-1.65M | 112.32%2.78M | 111.21%858K | 69.08%-3.95M | -102.86%-1.33M | 734.30%3.51M | -2,166.93%-22.56M |
| End cash Position | -31.10%9.37M | 4.98%10.46M | 49.81%20.84M | -10.79%13.6M | -10.79%13.6M | -71.38%10.82M | -78.09%9.96M | -76.11%13.91M | 29.97%15.24M | 29.97%15.24M |
| Free cash flow | -15.54%-23.61M | -31.09%-7.49M | -92.94%-7.19M | -62.04%-20.44M | -88.38%-5.7M | -105.31%-5.3M | -0.05%-5.71M | -187.42%-3.73M | -138.88%-12.61M | -94.60%-3.03M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
